Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Hypotheses: 1. Subjects with mild post-stroke cognitive impairment (PSCI) are at risk of
developing vascular dementia (VaD). Maraviroc treatment in patients suffering from mild PSCI
will halt its progression and improve cognitive outcome by affecting synaptic plasticity. 2.
CCR5 inhibition produces an anti-inflammatory and anti-atherogenic effect by lowering
macrophage infiltration and adhesion molecules. Thus, PSCI patients treated with Maraviroc
will present a better inflammatory profile and a deceleration of carotid atherosclerosis, vs.
placebo.
Objectives: To investigate the safety and efficacy of Maraviroc 150 mg and 600 mg per day vs.
placebo in patients with recent subcortical stroke who experience mild PSCI on
progression/improvement of clinical symptoms of post-stroke cognitive impairment, change in
disease biomarkers and inflammatory profile.
The study will include 150 participants aged 50-86 years treated with Maraviroc 150mg or
600mg per day compared to placebo for 12 months in 3 sites.
Phase:
Phase 2
Details
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborators:
Hadassah Medical Center Soroka University Medical Center